HBsAg Antibody

Western Blot: HBsAg Antibody [NB100-62652]

Western Blot: HBsAg Antibody [NB100-62652] - HepAD38 cells were treated with DFMO (50 uM, 100 uM), and the HBV core-associated DNA was extracted 3 days later and measured by Southern blot (upper panel). The levels of HBc and HBs were measured by Western blotting, and capsids levels were determined using a Native gel assay (lower panel). Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fcimb.2020.00158/full), licensed under a CC-BY license.

Western Blot: HBsAg Antibody [NB100-62652] -

Western Blot: HBsAg Antibody [NB100-62652] - DFMO decreases the HBV core-associated DNA & the HBc protein levels. (A) Determination of cytotoxicity of HepAD38 & HepG2.2.15 cells treated DFMO measured by the MTS assay. (B) HepAD38 cells were treated with DFMO (50 μM, 100 μM), & the HBV core-associated DNA was extracted 3 days later & measured by Southern blot (upper panel). The levels of HBc & HBs were measured by Western blotting, & capsids levels were determined using a Native gel assay (lower panel) as described above. (C) The levels of HBsAg in supernatant were measured by ELISA assay as described above. (D) HBV 3.5kb RNA levels were measured by real-time RT-PCR. (E) & (F) HepG2.2.15 cells treated with DFMO (50, 100 μM) for 3 days, then the levels of intracellular HBV DNA or HBsAg levels in the supernatant were detected by real-time PCR (E) or ELISA assay (F). (G) DFMO decreased the infection capacity of the HBV particles. HepAD38 cells in the absence of tetracycline were treated with DSMO or DFMO with indicated concentration for 3 days, & the HBV viral particles were then collected & added to the HepG2-NTCP cells. Five days later, the cytoplasmic viral DNA were extracted & measured by real-time PCR. RC, relaxed circular; DL, double stranded linear; SS, single stranded. Experiments were performed in triplicate, & data are represented as means ± SD. Statistical significance was determined by one-way ANOVA with the Tukey post-hoc test (*p < 0.05; ns, not significant). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32373551), licensed under a CC-BY license. Not internally tested by Novus Biologicals.